In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.

[1]  A. Zavascki,et al.  Vancomycin MIC for Methicillin-Resistant Coagulase-Negative Staphylococcus Isolates: Evaluation of the Broth Microdilution and Etest Methods , 2010, Journal of Clinical Microbiology.

[2]  J. Sohn,et al.  Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. , 2010, The Journal of antimicrobial chemotherapy.

[3]  K. Krause,et al.  Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. , 2010, The Journal of antimicrobial chemotherapy.

[4]  Ronald N. Jones,et al.  Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.

[5]  K. Stellrecht,et al.  Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin , 2008, Antimicrobial Agents and Chemotherapy.

[6]  K. Krause,et al.  In Vitro Activity of Telavancin against Resistant Gram-Positive Bacteria , 2008, Antimicrobial Agents and Chemotherapy.

[7]  D. Sahm,et al.  Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.

[8]  O. Cars,et al.  Pharmacodynamic Effects of Telavancin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Strains in the Presence of Human Albumin or Serum and in an In Vitro Kinetic Model , 2007, Antimicrobial Agents and Chemotherapy.

[9]  F. Tenover,et al.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Jerome J. Schentag,et al.  Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia , 2007, Antimicrobial Agents and Chemotherapy.

[11]  Ronald N. Jones,et al.  Comparison of Dalbavancin MIC Values Determined by Etest (AB BIODISK) and Reference Dilution Methods Using Gram-Positive Organisms , 2006, Journal of Clinical Microbiology.

[12]  L. Mortin,et al.  Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. , 2005, The Journal of infectious diseases.

[13]  G. Eliopoulos,et al.  Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia , 2004, Journal of Clinical Microbiology.

[14]  W. J. Novick.  Development of in vitro susceptibility testing criteria and quality control parameters , 1989 .